Clinical Trials · NCT01750398

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment
33
Start date
Jan 2013
Locations
1 site, United States
Primary endpoint
Patients With PSA <4 ng/mL at the End of the Study
View Gonadorelin compound reference